Dey launches EpiPen app

Share this article:
Dey launches EpiPen app
Dey launches EpiPen app
Mylan's Dey Pharma launched MyEpiPen App, designed to help patients with severe allergies and their caregivers cope with episodes of anaphylaxis.

The app, available for free download to iPhone, iPod Touch and iPad, allow patients and their caregivers to create and share profiles about severe allergies for sharing with friends, family members, teachers, school nurses, camp counselors, daycare providers and babysitters.

Features also include a how-to video for the EpiPen Auto-injector and a user guide slideshow to help users visualize the three-step injection process.

The app may be used without entering any information that identifies a user, the company said, and information that is recorded is stored only on the user's mobile device.

Around 12 million Americans, or 4%, have a food allergy that may put them at risk of anaphylaxis, said the company. Anaphylaxis, a potentially life-threatening allergic reaction, can also be triggered by insect stings, medications, latex or other allergens. Dey's EpiPen buys sufferers some time to seek medical attention.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...